aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa-overexpressed breast cancer

Oncology Research

Volumn 17, Issue 2, 2008, Pages 59-68

  Jin, Yi Ting ^a   Ying, Xue Xiang ^a   Hu, Yi Hong ^b   Zou, Qiang ^a,c   Wang, Hong Ying ^a   Xu, Yong Hua ^b  

^a FUDAN UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

5 FU; aPKC inhibitor; DCIK DCIK P cells; hASIP; Human breast cancer

Indexed keywords

ATYPICAL PROTEIN KINASE C ISOTYPE SPECIFIC INTERACTING PROTEIN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL POPULATION; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; EXON; GENE EXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GENE;

EID: 44849097288     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504008784523630     Document Type: Article

References (23)

1. Moscat, J.; Diaz-Meco, M. T. The atypical protein kinase Cs. EMBO Rep. 1:399-403; 2000.
2. Musashi, M.; Ota, S.; Shiroshita, N. The role of protein kinase C isoforms in cell proliferation and apoptosis. Int. J. Hematol. 72:12-19; 2000.
3. Liu, W. S.; Heckman, C. A. The sevenfold way of PKC regulation. Cell Signal. 10:529-542; 1998.
4. Ohno, S. Intercellular junctions and cellular polarity: The PAR-aPKC complex, a conserved core cassette playing fundamental roles in cell polarity. Curr. Opin. Cell Biol. 13:641-648; 2001.
5. Wodarz, A. Establishing cell polarity in development. Nat. Cell. Biol. 4:E39-44; 2002.
6. Lin, D.; Edwards, A. S.; Fawcett, J. P.; Mbamalu, G.; Scott, J. D.; Pawson, T. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat. Cell Biol. 2:540-547; 2000.
7. Hirose, T.; Izumi, Y.; Nagashima, Y.; Tamai-Nagai, Y.; Kurihara, H.; Sakai, T.; Suzuki, Y.; Yamanaka, T.; Suzuki, A.; Mizuno, K.; Ohno, S. Involvement of ASIP/PAR-3 in the promotion of epithelial tight junction formation. J. Cell Sci. 115:2485-2495; 2002.
8. Fang, C. M.; Xu, Y. H. Down-regulated expression of atypical PKC-binding domain deleted asip isoforms in human hepatocellular carcinomas. Cell Res. 11:223-229; 2001.
9. Hu, Y. H.; Fang, C. M.; Xu, Y. H. The effect of isoforms of the cell polatity, human ASIP, on the cell cycle and Fas/FasL-mediated apoptosis in human hepatoma cells. Cell. Mol. Life Sci. 62:1974-1983; 2005.
10. Modrek, B.; Lee, C. A genomic view of alternative splicing. Nat. Genet. 30:13-19; 2002.
11. Kanezaki, R.; Toki, T.; Yokoyama, M.; Yokoyama, M.; Yomogida, K.; Sugiyama, K.; Yamomoto, M. Transcription factor BACH1 is recruited to the nucleus by its novel alternative spliced isoform. J. Biol. Chem. 276:7278-7284; 2001.
12. Xiao, Z. S.; Thomas, R.; Hinson, T. K.; Quarles, L. D. Genomic structure and isoform expression of the mouse, rat and human Cbfa1/Osf2 transcription factor. Gene 214:187-197; 1998.
13. Pinedo, H. M.; Peters, G. F.; Fluorouracil: Biochemistry and pharmacology. J. Clin. Oncol. 6:1653-1664; 1988.
14. Li, M. H.; Ito, D.; Sanada, M.; Odani, T.; Hatori, M.; Iwase, M.; Nagumo, M. Effect of 5-fluorouracil on G1 phase cell cycle regulation in oral cancer cell lines. Oral Oncol. 40:63-70; 2004.
15. Linn, Y. C.; Hui, K. M. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk. Lymphoma 44:1457-1462; 2003.
16. Marten, A.; Schottker, B.; Ziske, C.; Weineck, S.; Buttgereit, P.; Huhn, D.; Sauerbruch, T.; Ingo, G.; Schmidt-Wolf, I. G. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA19-9 protein. J. Immunother. 23:464-472; 2000.
17. Marten, A.; Renoth, S.; von Lilienfeld-Toal, M.; Buttgereit, P.; Schakowski, F.; Glasmacher, A.; Sauerbruch, T.; Schmidt-Wolf, I. G. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86:1029-1037; 2001.
18. Marten, A.; Ziske, C.; Schottker, B.; Renoth, S.; Weineck, S.; Buttgereit, P.; Schakowski, F.; von Rucker, A.; Sauerbruch, T.; Schmidt-Wolf, I. G. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J. Immunother. 24:502-510; 2001.
19. Correa, I.; Plunkett, T. Updata on HER-2 as a target for cancer therapy, HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res. 3:399-403; 2001.
20. Zhou, J.; Zhong, Y. Breast cancer immunotherapy. Cell. Mol. Immunol. 1:247-255; 2004.
21. Mittendorf, E. A.; Starrer, C. E.; Foley, R. J.; Harris, K.; Jama, Y.; Shriver, C. D.; Ponniah, S.; Peoples, G. E. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 106:2309-2317; 2006.
22. Regale, R. P.; Weems, C.; Jamieson, L.; Khoor, A.; Edell, E. S.; Lohse, C. M.; Field, A. P. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res. 65:8905-8911; 2005.
23. Regale, R. P.; Weems, C.; Jamieson, L.; Copland, J. A.; Thompson, E. A.; Field, A. P. Atypical protein kinase C iota plays a critical role in human lung cancer cell growth and tumorigenicity. J. Biol. Chem. 280:31109-31115; 2005.